Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Hold

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 1.0%

Shares of SUPN traded down $0.32 during mid-day trading on Friday, hitting $31.67. The stock had a trading volume of 739,982 shares, compared to its average volume of 477,103. Supernus Pharmaceuticals has a fifty-two week low of $25.55 and a fifty-two week high of $40.28. The company has a market cap of $1.77 billion, a PE ratio of 28.53 and a beta of 0.71. The company's fifty day simple moving average is $32.15 and its two-hundred day simple moving average is $34.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after buying an additional 1,083 shares in the last quarter. Two Sigma Advisers LP lifted its position in Supernus Pharmaceuticals by 14.7% in the fourth quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after purchasing an additional 1,000 shares during the period. Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the period. Envestnet Asset Management Inc. boosted its stake in Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after purchasing an additional 3,495 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Supernus Pharmaceuticals by 63.6% during the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after purchasing an additional 6,867 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.